Want to join the conversation?
$LLY and AstraZeneca announced planned initiation of second phase 3 trial, called DAYBREAK-ALZ, that studies safety and efficacy of AZD3293 to treat mild Alzheimer's dementia. The trial, which began enrolling participants in 3Q16, has been shown in studies to lower levels of amyloid beta in cerebro-spinal fluid of people with Alzheimer's.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.